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Cells to Surgery Quiz
QUESTIONS
1.  Which of the following therapies results in the most rapid regeneration of normal skin when applied topically to the 
wound pictured above that was created by full-thickness skin excision?
 a. Low-dose tacrolimus monotherapy.
 b. AMD3100 monotherapy.
 c. AMD3100 + low-dose tacrolimus.
 d. Cyclosporin A.
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The image is from Dr. Nouri's personal collection of surgery photographs.
Questions relate to the image as well as to selected articles in JID, which are listed 
after the questions. Answers will be posted as supplementary material. We hope you 
enjoy this challenge.
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2.  If the time to complete wound healing after full-thickness excision were 32 days with 
no therapy, how many days would you expect it to take for a wound to heal if AMD3100 
and low-dose tacrolimus were applied in combination to the wound?
 a. 30 days.
 b. 28 days.
 c. 24 days.
 d. 20 days.
3.  Recruitment of stem cells by AMD3100 and low-dose tacrolimus combination therapy to 
wound sites leads to elevated expression of which of the following growth factors involved  
in wound healing?
 a. Basic fibroblast growth factor (b-FGF).
 b. Hepatocyte growth factor (HGF).
 c. Vascular endothelial growth factor (VEGF).
 d. All of the above.
TOPIC ARTICLE
The questions refer to the following article:
Lin Q, Wesson RN, Maeda H et al. (2014) Pharmacological mobilization of endogenous stem cells significantly promotes skin 
regeneration after full-thickness excision: the synergistic activity of AMD3100 and tacrolimus. J Dermatol Invest 134:2458–68
Answers are available as supplementary material at http://dx.doi.org/10.1038/jid.2014.279
